Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.
Epistemonikos ID: dca23b50cfc2fcd3527116343441ba332788030e
First added on: May 07, 2024